Safety signals, stratified by genotype.
Pharmacogenomics generates the prospective signal; pharmacovigilance captures the retrospective one. A consented, longitudinally modelled cohort can resolve safety signals that population-level surveillance cannot.
From suspected event to statutory report.
Structured capture from the clinical surface, the patient surface and passive signal detection.
The patient state as known at the time of the event, not as reconstructed afterwards.
Workflow with recorded assessor identity, method and reasoning.
Per-jurisdiction reporting timeframes, with escalation ahead of breach rather than after it.
Cohort analysis by genotype and metabolic phenotype across the twin population.
The under-priced asset.
Stratified signal detection has scientific standing, regulatory standing and partnership value simultaneously — and it accrues as a by-product of the clinical modules being used. It requires no additional product to be built, only that consent and outcome capture are right from the beginning.
Scientific
Signals resolved within genotypic and phenotypic subgroups that aggregate surveillance cannot separate.
Regulatory
A defined statutory customer, an existing obligation, and a workflow that is manual in most institutions today.
Partnership
Value to health systems, regulators and industry alike — shared where it bears on patient safety.
A bounded context, deliberately.
Pharmacovigilance runs as a distinct bounded context with its own case lifecycle, retention and statutory clock, coupled to the twin through the audit trail rather than embedded in the clinical decision path.
Bring pharmacovigilance to your service.
For health systems with a statutory reporting burden, and partners who need signals that aggregate surveillance cannot resolve.